Since we are already using Bristol-Myers Squibb's Ifosfamide it would make perfect sense that we would be using Bristol-Myers Squibb's Paraplatin Injection for the Von Hoff TD2 study...since that is the original drug not the generic for ovarian cancer... and since we have a relationship there already...